In yesterday’s Wall Street session, TG Therapeutics Inc (NASDAQ:TGTX) shares traded at $15.88, up 16.25% from the previous session.
TGTX stock price is now 5.63% away from the 50-day moving average and 18.51% away from the 200-day moving average. The market capitalization of the company currently stands at $2.45B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target reduced from $16 to $12, Goldman Upgraded its rating from Sell to Neutral for TG Therapeutics Inc (NASDAQ: TGTX). , while ‘BofA Securities’ rates the stock as ‘Underperform’
In other news, Lonial Sagar, Director sold 5,000 shares of the company’s stock on Mar 13 ’24. The stock was sold for $79,675 at an average price of $15.94. Upon completion of the transaction, the Director now directly owns 108,878 shares in the company, valued at $1.73 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 12 ’24, Director Charney Laurence N sold 22,000 shares of the business’s stock. A total of $351,340 was realized by selling the stock at an average price of $15.97. This leaves the insider owning 215,229 shares of the company worth $3.42 million. A total of 9.56% of the company’s stock is owned by insiders.
During the past 12 months, TG Therapeutics Inc has had a low of $6.46 and a high of $35.67. As of last week, the company has a debt-to-equity ratio of 0.69, a current ratio of 5.92, and a quick ratio of 5.18.
According to the Biotechnology Company, earnings per share came in at -0.28, beating analysts’ expectations of -0.37 by 0.09. This compares to -$0.39 EPS in the same period last year. The net profit margin was 5.42% and return on equity was 11.57% for TGTX. The company reported revenue of $43.97 million for the quarter, compared to $81000.0 a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 54183.95 percent. For the current quarter, analysts expect TGTX to generate $54.61M in revenue.
